tafamidis   

GtoPdb Ligand ID: 8378

Synonyms: FX-1006 | Vyndamax® | Vyndaqel®
tafamidis is an approved drug (EMA and UK (2011), FDA (2019))
Compound class: Synthetic organic
Comment: Tafamidis binds potently and selectively to transthyretin (TTR), stabilising protein tetramers, thereby inhibiting the formation of amyloid fibrils [2]. The trade name for this drug is Vyndaqel which contains tafamidis meglumine (PubChem CID 24970412). The Vyndamax brand contains tafamidis parent molecule.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 63.33
Molecular weight 306.98
XLogP 4.02
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Clc1cc(Cl)cc(c1)c1nc2c(o1)cc(cc2)C(=O)O
Isomeric SMILES Clc1cc(Cl)cc(c1)c1nc2c(o1)cc(cc2)C(=O)O
InChI InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)
InChI Key TXEIIPDJKFWEEC-UHFFFAOYSA-N
Classification
Compound class Synthetic organic
Approved drug? Yes (EMA and UK (2011), FDA (2019))
IUPAC Name
2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
International Nonproprietary Names
INN number INN
9094 tafamidis
Synonyms
FX-1006 | Vyndamax® | Vyndaqel®
Database Links
CAS Registry No. 594839-88-0
ChEMBL Ligand CHEMBL2103837
DrugCentral Ligand 4192
GtoPdb PubChem SID 252166590
PubChem CID 11001318
RCSB PDB Ligand 3MI
Search Google for chemical match using the InChIKey TXEIIPDJKFWEEC-UHFFFAOYSA-N
Search Google for chemicals with the same backbone TXEIIPDJKFWEEC
Search PubMed clinical trials tafamidis
Search PubMed titles tafamidis
Search PubMed titles/abstracts tafamidis
Search UniChem for chemical match using the InChIKey TXEIIPDJKFWEEC-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone TXEIIPDJKFWEEC
SynPHARM 82072 (in complex with transthyretin)